Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Kuschyk, Jürgen [VerfasserIn]   i
 Röger, Susanne [VerfasserIn]   i
 Schneider, Raphaela [VerfasserIn]   i
 Streitner, Florian [VerfasserIn]   i
 Stach-Jablonski, Ksenija [VerfasserIn]   i
 Rudic, Boris [VerfasserIn]   i
 Weiß, Christel [VerfasserIn]   i
 Schimpf, Rainer [VerfasserIn]   i
 Papavassiliu, Theano [VerfasserIn]   i
 Borggrefe, Martin [VerfasserIn]   i
Titel:Efficacy and survival in patients with cardiac contractility modulation
Titelzusatz:long-term single center experience in 81 patients
Verf.angabe:Jürgen Kuschyk, Susanne Roeger, Raphaela Schneider, Florian Streitner, Ksenija Stach, Boris Rudic, Christel Weiß, Rainer Schimpf, Theano Papavasilliu, Benny Rousso, Daniel Burkhoff, Martin Borggrefe
E-Jahr:2015
Jahr:20 January 2015
Umfang:6 S.
Fussnoten:Gesehen am 29.08.2017
Titel Quelle:Enthalten in: International journal of cardiology
Ort Quelle:Amsterdam [u.a.] : Elsevier Science, 1981
Jahr Quelle:2015
Band/Heft Quelle:183(2015), Seite 76-81
ISSN Quelle:1874-1754
Abstract:To analyze long-term efficacy and survival in patients with chronic heart failure treated with cardiac contractility modulation. 81 patients implanted with a CCM device between 2004 and 2012 were included in this retrospective analysis. Changes in NYHA class, ejection fraction (EF), Minnesota Living with Heart Failure Questionnaire, NT-proBNP and peak VO2 were analyzed during a mean follow up of 34.2±28months (6-123months). Observed mortality rate was compared with that predicted by the MAGGIC Score. Patients were 61±12years old with EF 23±7%. Heart failure was due to ischemic (n=48, 59.3%) or idiopathic dilated (n=33, 40.7%) cardiomyopathy. EF increased from 23.1±7.9 to 29.4±8.6% (p<0.05), mean NT-proBNP decreased from 4395±3818 to 2762±3490ng/l (p<0.05) and mean peak VO2 increased from 13.9±3.3 to 14.6±3.5ml/kg/min (p=0.1). The overall clinical responder rate (at least 1 class improvement of NYHA within 6months or last follow-up) was 74.1%. 21 (25.9%) patients died during follow up, 11 (52.4%) due to cardiac conditions and 10 (47.6%) due to non-cardiac conditions. Mortality rates at 1 and 3years were 5.2% and 29.5% compared to mortality rates estimated from the MAGGIC risk score of 18.4% (p<0.001) and 40% (p=ns), respectively. Log-Rank analysis of all events through 3years of follow-up, however, was significantly less than predicted (p=0.022). CCM therapy improved quality of life, exercise capacity, NYHA class, EF and NT-proBNP levels during long-term follow up. Mortality rates appeared to be lower than estimated from the MAGGIC score.
DOI:doi:10.1016/j.ijcard.2014.12.178
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: http://dx.doi.org/10.1016/j.ijcard.2014.12.178
 Volltext: http://www.sciencedirect.com/science/article/pii/S0167527315000583
 DOI: https://doi.org/10.1016/j.ijcard.2014.12.178
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Cardiac contractility modulation
 Device therapy
 Heart failure
K10plus-PPN:1562807633
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68154845   QR-Code
zum Seitenanfang